Journal: Scientific Reports

Article Title: Evidence, detailed characterization and clinical context of complement activation in acute multisystem inflammatory syndrome in children

doi: 10.1038/s41598-022-23806-5

Figure Lengend Snippet: Key resources.

Article Snippet: Polyclonal antiserum to human C1 inhibitor (C1 esterase) , Quidel , Cat# A300.

Techniques: Binding Assay, Recombinant, Enzyme-linked Immunosorbent Assay, Software

Journal: Clinical immunology (Orlando, Fla.)

Article Title: Applying Complement Therapeutics to Rare Diseases

doi: 10.1016/j.clim.2015.08.009

Figure Lengend Snippet: Simplified scheme of the complement cascade. In blue: proteins of the classical and lectins pathways; green: convertases of the classical and lectins pathways; orange: proteins of the alternative pathway; purple: convertases of the alternative pathway; red: proteins common to all the pathways; gray: soluble regulators. Complement cell receptors are depicted at the surface of the host cell. Red symbols: points of therapeutic interventions in rare diseases. Abbreviations: C1INH-C1 inhibitor, C4BP-C4b binding protein, CR-complement receptor, DAF-decay accelerating factor, FB-factor B, FD-factor D, FH-factor H, FI-factor I, MAC-membrane attack complex, MBL-mannose binding lectin, MCP-membrane cofactor protein. *ALN-CC5 inhibits C5 expression.

Article Snippet: Human C1 esterase inhibitor , Alpha Therapeutic Corporation (now Grifols) , C1r, C1s, MASP-1, MASP – 2, other proteases , 8/21/1996-FDA , Designated , Treatment and prevention of HAE caused by C1-esterase inhibitor deficiency-Undisclosed development stage.

Techniques: Binding Assay, Membrane, Expressing

Journal: Clinical immunology (Orlando, Fla.)

Article Title: Applying Complement Therapeutics to Rare Diseases

doi: 10.1016/j.clim.2015.08.009

Figure Lengend Snippet: Impact of drug candidates on complement-mediated functions. Abbreviations: AP-alternative pathway, CP-classical pathway, C5aR-C5a receptor 1, C1-INH-C1 inhibitor, FD-factor D, FH-factor H, LP-lectin pathway, MAC-membrane attack complex, MASP-2-mannose binding lectin. Dotted lines indicate impact in the complement functions downstream of C3 due to less generation of C3b. Full lines indicate impact on C5-mediated functions due to inhibited amplification loop.

Article Snippet: Human C1 esterase inhibitor , Alpha Therapeutic Corporation (now Grifols) , C1r, C1s, MASP-1, MASP – 2, other proteases , 8/21/1996-FDA , Designated , Treatment and prevention of HAE caused by C1-esterase inhibitor deficiency-Undisclosed development stage.

Techniques: Membrane, Binding Assay, Amplification

Journal: Clinical immunology (Orlando, Fla.)

Article Title: Applying Complement Therapeutics to Rare Diseases

doi: 10.1016/j.clim.2015.08.009

Figure Lengend Snippet: List of complement-related drugs with orphan status by the FDA and EMEA.

Article Snippet: Human C1 esterase inhibitor , Alpha Therapeutic Corporation (now Grifols) , C1r, C1s, MASP-1, MASP – 2, other proteases , 8/21/1996-FDA , Designated , Treatment and prevention of HAE caused by C1-esterase inhibitor deficiency-Undisclosed development stage.

Techniques: Recombinant, Transplantation Assay, Infection

Journal: Clinical immunology (Orlando, Fla.)

Article Title: Applying Complement Therapeutics to Rare Diseases

doi: 10.1016/j.clim.2015.08.009

Figure Lengend Snippet: List of complement-related drugs without orphan designation in pre-clinical and clinical development for rare diseases.

Article Snippet: Human C1 esterase inhibitor , Alpha Therapeutic Corporation (now Grifols) , C1r, C1s, MASP-1, MASP – 2, other proteases , 8/21/1996-FDA , Designated , Treatment and prevention of HAE caused by C1-esterase inhibitor deficiency-Undisclosed development stage.

Techniques: